Sponsored

ImpediMed’s HF-Dex™ abstract published- what does its significant data reveal?

Summary

  • ImpediMed Limited’s (ASX:IPD) HF-Dex™ abstract has been published online.
  • It was accepted for poster presentation at the prestigious American College of Cardiology’s (ACC) 70th Virtual Annual Scientific Session, slated for 15-17 May 2021.
  • The data showed heart failure patients with a SOZO Hf-Dex level of over 51% at the time of hospital discharged are 4x more likely to be readmitted to a hospital within 45days.
  • Hospital readmissions is an enormous burden on the US healthcare system costing an estimated $A 31 billion annually with Heart Failure the leading cause of readmissions
  • The data is significant and demonstrates that established normative range data collected using SOZO® can be useful in risk-stratifying patients.

The stock of med-tech Company ImpediMed Limited (ASX:IPD) rose by over 8% on 4 May 2021 on trading volume of over 2.8 million shares. IPD closed at quoted AU$0.13 equating to a  market capitalisation of  AU$194 million.

ALSO READ: ImpediMed stock jumps on FDA nod for SOZO® heart failure index

Copyright © 2021 Kalkine Media Pty Ltd

The positive sentiment was seemingly built after bioimpedance spectroscopy (BIS) technology pioneer announced the publication of an HF-Dex™ abstract.

INTERESTING READ: Will ImpediMed’s growing business continue in the same vein?

Publication Of HF-Dex™ Abstract

ImpediMed’s HF-Dex™ abstract has been published online in the Journal of the American College of Cardiology Abstract Supplement.

The abstract was accepted for poster presentation at the ACC 70th Virtual Annual Scientific Session, scheduled to be held between 15-17 May 2021. The ACC annual meeting is a leading scientific session for the US cardiology field and has global reach.

RELATED READ: Impedimed’s SOZO ® Heart Failure Abstract Accepted For Poster Presentation At ACC

Presenting data at the esteemed forum provides important validation to ImpediMed’s technology, says Richard Carreon, Managing Director and the CEO. Notably, the Company’s technology has the potential to integrate with current patient care pathways to reduce hospital re-admissions.

“The data from this abstract is significant and demonstrates that the established normative range data gathered by using SOZO can be very useful in risk-stratifying patients,” he adds.

ALSO READ: A feather in ImpediMed’s SOZO® cap: Clinical utility manuscript published

Significant Findings

The recently published paper, Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy, has established the potential clinical utility when a heart failure patient’s HF-DexTM level exceeded 51% and Extracellular Fluid expressed as a percentage of Total Body Water.

Notably, this information is likely to be a clinically relevant support for physicians in stratifying clinical risk and monitoring fluid volume of heart failure patients.

ImpediMed’s abstract, titled “Bioimpedance Spectroscopy Measurement of Ongoing Fluid Overload PostDischarge from Hospitalization for Decompensated Heart Failure” demonstrates the potential value of the SOZO® HF-DexTM measure.

SOZO® with HF-DexTM has the potential to identify patients with fluid overload.

GOOD READ: How ImpediMed’s BIS device SOZO® is changing digital health landscape

US Healthcare System Facts

The cost of hospital re-admissions is enormous - an estimated $31 billion annually. Besides, hospitals are required to cover the cost of re-admissions in the initial 30 days of discharge.

Medicare fines hospitals for high re-admission rates. In 2019, 82% of hospitals in the program received re-admissions penalties.

Besides, a study conducted by the Agency for Healthcare Research and Quality on re-admissions from 2011 found congestive heart failure as the leading cause for re-admissions among Medicare patients with nearly one in four re-admitted within 30 days.

ALSO READ: ImpediMed’s SOZO® testing surpasses 200,000-patient test mark


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK